These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28884856)

  • 1. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
    Nakase H; Motoya S; Matsumoto T; Watanabe K; Hisamatsu T; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    Aliment Pharmacol Ther; 2017 Nov; 46(9):873-882. PubMed ID: 28884856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
    Assa A; Matar M; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Shamir R
    Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
    Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
    Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.
    Mazor Y; Almog R; Kopylov U; Ben Hur D; Blatt A; Dahan A; Waterman M; Ben-Horin S; Chowers Y
    Aliment Pharmacol Ther; 2014 Sep; 40(6):620-8. PubMed ID: 25039584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
    Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
    J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Selvaraj F; Princen F; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Gearry RB; Selby W; Bell SJ; Brown SJ; Connell WR
    J Crohns Colitis; 2018 May; 12(6):653-661. PubMed ID: 29385469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.
    Zittan E; Kabakchiev B; Milgrom R; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    J Crohns Colitis; 2016 May; 10(5):510-5. PubMed ID: 26783345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study.
    Ungar B; Engel T; Yablecovitch D; Lahat A; Lang A; Avidan B; Har-Noy O; Carter D; Levhar N; Selinger L; Neuman S; Natour OH; Yavzori M; Fudim E; Picard O; Kopylov U; Chowers Y; Naftali T; Broide E; Shachar E; Eliakim R; Ben-Horin S
    Am J Gastroenterol; 2018 Jun; 113(6):890-898. PubMed ID: 29867175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
    Vande Casteele N; Baert F; Bian S; Dreesen E; Compernolle G; Van Assche G; Ferrante M; Vermeire S; Gils A
    J Crohns Colitis; 2019 Sep; 13(10):1248-1256. PubMed ID: 30820530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.
    Verstockt B; Moors G; Bian S; Van Stappen T; Van Assche G; Vermeire S; Gils A; Ferrante M
    Aliment Pharmacol Ther; 2018 Oct; 48(7):731-739. PubMed ID: 30109889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
    Kato M; Sugimoto K; Ikeya K; Takano R; Matsuura A; Miyazu T; Ishida N; Tamura S; Tani S; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Furuta T; Hanai H
    PLoS One; 2021; 16(7):e0254548. PubMed ID: 34242369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
    Bond A; Asher R; Jackson R; Sager K; Martin K; Kneebone A; Philips S; Taylor W; Subramanian S
    Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):271-6. PubMed ID: 26657455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease.
    Watanabe K; Matsumoto T; Hisamatsu T; Nakase H; Motoya S; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):542-549.e1. PubMed ID: 29104132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.
    Bodini G; Giannini EG; Furnari M; Marabotto E; Baldissarro I; Del Nero L; Assandri L; Moscatelli A; Savarino V; Savarino E
    J Gastrointestin Liver Dis; 2015 Dec; 24(4):451-6. PubMed ID: 26697571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies.
    Cordero-Coma M; Calleja-Antolín S; Garzo-García I; Nuñez-Garnés AM; Álvarez-Castro C; Franco-Benito M; Ruiz de Morales JG
    Ophthalmology; 2016 Dec; 123(12):2618-2625. PubMed ID: 27692527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
    Sharma S; Eckert D; Hyams JS; Mensing S; Thakkar RB; Robinson AM; Rosh JR; Ruemmele FM; Awni WM
    Inflamm Bowel Dis; 2015 Apr; 21(4):783-92. PubMed ID: 25723614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
    Ungar B; Kopylov U; Engel T; Yavzori M; Fudim E; Picard O; Lang A; Williet N; Paul S; Chowers Y; Bar-Gil Shitrit A; Eliakim R; Ben-Horin S; Roblin X
    Aliment Pharmacol Ther; 2017 Jan; 45(2):276-282. PubMed ID: 27862102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.